Funder
National Center for Advancing Translational Sciences
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology
Reference39 articles.
1. Lugowska, I., Kosela-Paterczyk, H., Kozak, K., & Rutkowski, P. (2015). Trametinib: A MEK inhibitor for management of metastatic melanoma. OncoTargets and Therapy,
8, 2251–2259.
2. Zhao, Y., & Adjei, A. A. (2014). The clinical development of MEK inhibitors. Nature Reviews Clinical Oncology,
11, 385–400.
3. Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., 3rd, Rasco, D., et al. (2013). A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer,
49, 2077–2085.
4. Bridgeman, V. L., Wan, E., Foo, S., Nathan, M. R., Welti, J. C., Frentzas, S., et al. (2016). Preclinical evidence that trametinib enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Molecular Cancer Therapeutics,
15, 172–183.
5. Pervere, L. M., Rakshit, S., Schrock, A. B., Miller, V. A., Ali, S. M., Velcheti, V. (2017). Durable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non-small-cell lung cancer. Clinical Lung Cancer,
18(3), e211–e213.
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献